Evaluation of Cardiotoxicity and Hypertension in Patients With Non Metastatic Castration Resistant Prostatic Carcinoma

Study Overview
=================
Brief Summary
-----------------
This is a prospective observational study on a cohort of patients with castration-resistant prostate cancer M0, treated with Apalutamide, at the Oncology Unit of the Andrea Tortora Hospital of Pagani. Data will be collected on the patient's clinical history and the treatments carried out until the start of therapy with Apalutamide. At that time the study will be described to the patient and informed consent will be given. In case of a favorable opinion from the patient, the CRF will be filled in. Patients with CRPC M0 treated with Apalutamide, belonging to the Oncology Unit of the Pagani Hospital Andrea Tortora and of the other Oncology Units of the ASL of Salerno (Hospital of Vallo della Lucania) will be studied with the possibility of enrollment also from other Centers outside the Salerno ASL.

Detailed Description
-----------------
The CRPC M0 patient will be identified by PET PSMA, or CT scan and Bone Scanning at the clinician's discretion based on the physical examination performed at the patient's first access. The reassessment of the disease status is to be repeated by PET-PSMA, CT scan or bone scan (in relation to the examination carried out at baseline) in a period of time ranging from 6 to 12 months after the first access, based on the assessment of the health status of the patient and tolerability to treatment after careful evaluation by the clinician. The blood chemistry routine including CBC with white blood cell formula will be repeated every 30 days. The patient will be provided with a blood pressure monitoring diary every 30 days. The measurement of cardiac markers will be performed every 60 days. The evaluation of the cardiological function will be carried out by means of ECG, echocardiography with determination of the LVEF, 24-hour Holter blood pressure every 6 months. Bone mineral density assessment will be monitored by MOC-DEXA every 6 months. Possible drug interactions with Apalutamide will be identified. Primary objective: -Evaluation of arterial hypertension, by periodic measurement of blood pressure every week (1-3 times), creation of a weekly blood pressure diary, 24-hour blood pressure holter every six months, with stratification of patients under treatment according to the degree of AI found. Secondary objectives: Evaluation of cardiological toxicity, through the execution of ECG, periodic echocardiography for the evaluation of the ejection fraction of the left ventricle, cardiac markers (troponin, CK-MB, pro-BNP) Assessment of the biochemical response, such as a 50% reduction in total PSA compared to baseline in patients receiving apalutamide; Evaluation of the change in blood chemistry parameters in the patient being treated with Apalutamide; Relationship between changes in blood chemistry parameters and time to the onset of metastases, assessed by PET PSMA or bone scan or CT scan; Relationship between changes in blood chemistry parameters and overall survival; Relationship between changes in blood chemistry parameters and occurrence of serious adverse events; Association between basophil counts and appearance of skin rash; Evaluation of drug interactions with Apalutamide.

Official Title
-----------------
Evaluation of Cardiotoxicity and Hypertension in Patients With Non Metastatic Castration Resistant Prostatic Carcinoma

Conditions
-----------------
Castration-resistant Prostate Cancer

Intervention / Treatment
-----------------
* Other: No Intervention on patients


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: CRPC patients without evidence of distant metastasis are eligible Exclusion Criteria: -
Sexes Eligible for Study
-----------------
Male

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| CRPC patients<br>CRPC patients without evidence of distant metastasis are eligible | Other: No Intervention on patients<br>* No Intervention on patients<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation of arterial hypertension, by creation of a weekly blood pressure diary, 24-hour blood pressure holter every six months | Evaluation of arterial hypertension, by creation of a weekly blood pressure diary, 24-hour blood pressure holter every six months | Almost 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assessment of biochemical response, such as 50% change in total PSA from baseline in patients receiving apalutamide | Assessment of biochemical response, such as 50% change in total PSA from baseline in patients receiving apalutamide | Almost 1 year | 
| Relationship between changes in blood chemistry parameters and time to onset of metastases, assessed by PET PSMA or bone scan or CT scan | Relationship between changes in blood chemistry parameters and time to onset of metastases, assessed by PET PSMA or bone scan or CT scan | Almost 1 year | 
| Relationship between changes in blood chemistry parameters and overall survival | Relationship between changes in blood chemistry parameters and overall survival | Almost 1 year | 
| Relationship between changes in blood chemistry parameters and occurrence of serious adverse events | Relationship between changes in blood chemistry parameters and occurrence of serious adverse events | Almost 1 year | 
| Association between basophil count and appearance of skin rash | Association between basophil count and appearance of skin rash | Almost 1 year | 
| Evaluation of drug interactions with Apalutamide | Evaluation of drug interactions with Apalutamide | Almost 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Apalutamide, Oncological patients, Cancer, CRPC